Denmark's ChemoMetec annual revenue rises on new instrument demand, services growth

ChemoMetec A/S

10/09/2026 19:48

Overview
Denmark cell counting instrument maker's annual revenue grew 3% yr/yr to DKK 511.1 mln
EBITDA rose to DKK 281.3 mln, driven by revenue growth and reduced staff costs
Company will not propose a dividend for the year due to ongoing share buy-back programme

Outlook
Chemometec expects 2026/27 revenue of DKK 545-575 mln
Company guides 2026/27 EBITDA in the range of DKK 300-315 mln
Chemometec to focus on marketing XcytoMatic products and expanding partnerships in 2026/27

Result Drivers
NEW PRODUCT SALES - Growth driven by increased sales of new instruments, especially XcytoMatic products
CUSTOMER AUTOMATION DEMAND - Increased demand for automation and integration solutions supported product sales
REGIONAL PERFORMANCE - Revenue growth in Europe and rest of world offset decline in USA/Canada

Company press release: ID:nGNE6nlyHY

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
 
DKK 511.10 mln
 
FY EBITDA
 
DKK 281.30 mln
 
FY EBITDA Margin
 
55%
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Chemometec A/S is DKK650.00, about 26.2% above its September 9 closing price of DKK515.00
The stock recently traded at 38 times the next 12-month earnings vs. a P/E of 29 three months ago

Reuters Recommended Reads
Sept 9 - Swiss medical device maker Medacta H1 revenue rises on Asia Pacific, EMEA strength
Sept 9 - Israel's Nano-X Imaging Q2 revenue misses estimates
Sept 9 - Cooper Companies cuts annual profit forecast on weak contact lens demand 

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)